LENZ Therapeutics (LENZ) Payables (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Payables data on file, last reported at $10.9 million in Q1 2026.

• On a quarterly basis, Payables rose 198.52% year-over-year to $10.9 million in Q1 2026; TTM through Mar 2026 was $10.9 million, a 198.52% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, down 2.11% from the prior year.
• Payables for Q1 2026 stood at $10.9 million, up from $4.2 million in the prior quarter.
• Over the last five years, Payables for LENZ reached as high as $10.9 million in Q1 2026 and fell as low as $2.0 million in Q1 2023.
• Historically, Payables has averaged $4.2 million across 5 years, with a median of $3.8 million in 2023.
• Across the five-year window, Payables surged 257.98% in 2024 and tumbled 48.66% in 2025, its largest moves.
• Year by year, Payables stood at $2.6 million in 2022, then soared by 118.98% to $5.7 million in 2023, then declined by 25.46% to $4.3 million in 2024, then dropped by 2.11% to $4.2 million in 2025, then surged by 162.28% to $10.9 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $10.9 million in Q1 2026, $4.2 million in Q4 2025, and $4.3 million in Q3 2025.